Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMBNASDAQ:NKTRNASDAQ:OMERNASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$12.57-0.6%$10.59$7.75▼$19.93$95.97M0.4926,199 shs20,053 shsNKTRNektar Therapeutics$0.61-5.6%$0.72$0.43▼$1.93$112.78M0.621.83 million shs2.83 million shsOMEROmeros$6.35+0.2%$7.55$3.00▼$13.60$370.24M2.42585,759 shs374,402 shsPCRXPacira BioSciences$25.16+0.0%$24.64$11.16▼$31.67$1.16B0.56986,267 shs726,563 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-10.54%+9.82%+45.12%-11.05%-1.63%NKTRNektar Therapeutics-6.58%-13.33%+16.33%-15.53%-61.09%OMEROmeros-6.90%-12.07%-10.20%-31.01%+72.75%PCRXPacira BioSciences-2.56%-6.85%+8.87%-7.16%-5.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences3.4501 of 5 stars3.33.00.04.71.40.80.0NKTRNektar Therapeutics4.2108 of 5 stars3.53.00.04.22.52.50.6OMEROmeros3.5395 of 5 stars3.40.00.04.42.81.70.6PCRXPacira BioSciences2.2316 of 5 stars1.21.00.03.93.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.67Moderate Buy$33.00162.63% UpsideNKTRNektar Therapeutics 3.00Buy$4.50642.57% UpsideOMEROmeros 2.80Moderate Buy$22.50254.33% UpsidePCRXPacira BioSciences 2.33Hold$26.675.99% UpsideCurrent Analyst Ratings BreakdownLatest OMER, PCRX, NKTR, and ASMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/11/2025NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$1.00 ➝ $2.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/8/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/8/2025PCRXPacira BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $65.004/1/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/1/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025ASMBAssembly BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$31.003/24/2025ASMBAssembly BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/21/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/14/2025NKTRNektar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$6.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M3.37N/AN/A$7.50 per share1.68NKTRNektar Therapeutics$98.43M1.15N/AN/A$0.69 per share0.88OMEROmerosN/AN/AN/AN/A($0.40) per shareN/APCRXPacira BioSciences$700.97M1.66$3.87 per share6.50$18.74 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$61.23M-$6.72N/AN/AN/A-144.05%-121.46%-34.56%5/14/2025 (Estimated)NKTRNektar Therapeutics-$276.06M-$0.59N/AN/AN/A-180.70%-173.28%-46.31%5/8/2025 (Estimated)OMEROmeros-$117.81M-$2.70N/AN/AN/AN/AN/A-49.92%5/13/2025 (Estimated)PCRXPacira BioSciences$41.96M-$2.19N/A9.79N/A-13.07%13.42%7.19%5/8/2025 (Estimated)Latest OMER, PCRX, NKTR, and ASMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025OMEROmeros-$0.6033N/AN/AN/A$0.40 millionN/A5/14/2025Q1 2025ASMBAssembly Biosciences-$2.01N/AN/AN/A$7.41 millionN/A5/8/2025Q1 2025NKTRNektar Therapeutics-$0.17N/AN/AN/A$15.61 millionN/A5/8/2025Q1 2025PCRXPacira BioSciences$0.61N/AN/AN/A$176.35 millionN/A3/31/2025Q4 2024OMEROmeros-$0.71-$0.63+$0.08-$0.54$0.40 millionN/A3/20/2025Q4 2024ASMBAssembly Biosciences-$1.75-$1.57+$0.18-$1.57$7.05 million$7.36 million3/12/2025Q4 2024NKTRNektar Therapeutics-$0.18$0.15+$0.33$0.03$36.65 million$29.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A2.362.36NKTRNektar TherapeuticsN/A4.244.24OMEROmerosN/A2.962.96PCRXPacira BioSciences0.512.251.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%NKTRNektar Therapeutics75.88%OMEROmeros48.79%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.10%NKTRNektar Therapeutics3.71%OMEROmeros12.30%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.64 million6.03 millionOptionableNKTRNektar Therapeutics220186.10 million177.62 millionOptionableOMEROmeros21058.31 million50.82 millionOptionablePCRXPacira BioSciences72046.29 million43.22 millionOptionableOMER, PCRX, NKTR, and ASMB HeadlinesRecent News About These CompaniesDimensional Fund Advisors LP Decreases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 7 at 3:48 AM | marketbeat.comPacira BioSciences soars 52% following InvestingPro’s October Fair Value alertMay 5 at 7:32 PM | investing.com5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings EstimatesMay 5 at 10:15 AM | zacks.comSchonfeld Strategic Advisors LLC Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 5 at 5:11 AM | marketbeat.comMarshall Wace LLP Sells 482,336 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)May 3, 2025 | marketbeat.comPacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee OsteoarthritisMay 2, 2025 | globenewswire.comBrokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $26.67May 2, 2025 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by PDT Partners LLCMay 1, 2025 | marketbeat.comPacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from BrokeragesMay 1, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Up 3.5% - Still a Buy?April 30, 2025 | marketbeat.comLPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX)April 30, 2025 | marketbeat.comAnalysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out forApril 29, 2025 | zacks.comPacira’s gene therapy shows sustained benefits in trial for knee osteoarthritisApril 29, 2025 | finance.yahoo.comPacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025April 29, 2025 | globenewswire.comPacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the KneeApril 28, 2025 | globenewswire.comInvesco Ltd. Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)April 28, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of PCRX Q1 EarningsApril 27, 2025 | marketbeat.comCanada Pension Plan Investment Board Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)April 27, 2025 | marketbeat.comBarclays PLC Grows Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)April 26, 2025 | marketbeat.comNatixis Invests $1.74 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)April 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBroadcom's VMware Deal Lifts AVGO Despite Complaints By Leo Miller | April 28, 2025View Broadcom's VMware Deal Lifts AVGO Despite Complaints AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?By Leo Miller | May 1, 2025View AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?With a 60%+ Upside, There’s Plenty to Love About LovesacBy Jea Yu | April 20, 2025View With a 60%+ Upside, There’s Plenty to Love About LovesacWill CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains?By Chris Markoch | April 8, 2025View Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains?Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostBy Leo Miller | May 7, 2025View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostOMER, PCRX, NKTR, and ASMB Company DescriptionsAssembly Biosciences NASDAQ:ASMB$12.56 -0.08 (-0.59%) Closing price 03:59 PM EasternExtended Trading$13.50 +0.93 (+7.43%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Nektar Therapeutics NASDAQ:NKTR$0.61 -0.04 (-5.61%) Closing price 03:59 PM EasternExtended Trading$0.61 +0.01 (+1.16%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Omeros NASDAQ:OMER$6.35 +0.01 (+0.16%) Closing price 04:00 PM EasternExtended Trading$6.34 0.00 (-0.08%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Pacira BioSciences NASDAQ:PCRX$25.16 +0.01 (+0.04%) Closing price 03:59 PM EasternExtended Trading$25.17 +0.01 (+0.04%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
